| Added by | André Pèlegrin |
|---|---|
| Group name | EquipeAP |
| Item Type | Journal Article |
| Title | Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France |
| Creator | Martin et al. |
| Author | Camille Martin |
| Author | Claire Kizlik-Masson |
| Author | André Pèlegrin |
| Author | Hervé Watier |
| Author | Marie-Claude Viaud-Massuard |
| Author | Nicolas Joubert |
| Abstract | The annual "Antibody Industrial Symposium", co organized by LabEx MAbImprove, MabDesign and Polepharma, was held in Tours, France on June 27-28, 2017. The focus was on antibody-drug-conjugates (ADCs), new entities which realize the hope of Paul Ehrlich's magic bullet. ADCs result from the bioconjugation of a highly cytotoxic drug to a selective monoclonal antibody, which acts as a vector. Building on knowledge gained during the development of three approved ADCs, brentuximab vedotin (Adcetris®), ado trastuzumab emtansine (Kadcyla®) and inotuzumab ozogamicin (Besponsa®), and the many ADCs in development, this meeting addressed strategies and the latest innovations in the field from fundamental research to manufacturing. |
| Publication | mAbs |
| Volume | 10 |
| Issue | 2 |
| Pages | 210-221 |
| Date | 2018 Feb/Mar |
| Journal Abbr | MAbs |
| Language | eng |
| DOI | 10.1080/19420862.2017.1412130 |
| ISSN | 1942-0870 |
| Short Title | Antibody-drug conjugates |
| Library Catalog | PubMed |
| Extra | PMID: 29239690 PMCID: PMC5825198 |
| Tags | ADC, bioconjugation, collaboration, immunoconjugate, meeting |
| Date Added | 2018/08/28 - 11:20:04 |
| Date Modified | 2019/05/14 - 12:20:51 |
Institut de Recherche en Cancérologie de
